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Late Stent Recoil of the Bioabsorbable
Everolimus-Eluting Coronary Stent and
its Relationship With Plaque Morphology
Shuzou Tanimoto, MD,* Nico Bruining, PHD,* Ron T. van Domburg, PHD,* David Rotger, BSC,†
Petia Radeva, PHD,† Jurgen M. Ligthart, BSC,* Patrick W. Serruys, MD, PHD, FACC*
Rotterdam, the Netherlands; and Bellaterra, Spain
Objectives This study sought to evaluate late recoil of a novel bioabsorbable everolimus-eluting coronary stent (BVS), which
is composed of a poly-L-lactic acid backbone, coated with a bioabsorbable polymer containing everolimus.
Background Little is known about the mechanical behavior of bioabsorbable polymer stents after deployment in diseased
human coronary arteries.
Methods The study population consisted of 16 patients, who were treated with elective BVS implantation for single de
novo native coronary artery lesions and were followed at 6 months. All patients underwent an intravascular ultra-
sound examination at post-procedure and follow-up. A total of 484 paired cross-sectional areas (CSAs) were ac-
quired and analyzed. Late absolute stent recoil was defined as stent area at post-procedure (X)  stent area at
follow-up (Y). Late percent stent recoil was defined as (X  Y)/X  100. In each CSA, plaque morphology was
assessed qualitatively and classified as calcific, fibronecrotic, or fibrocellular plaque.
Results Late absolute and percent recoil of the BVS was 0.65  1.71 mm2 (95% confidence interval [CI]: 0.49 to 0.80
mm2) and 7.60  23.3% (95% CI: 5.52% to 9.68%). Calcified plaques resulted in significantly less late recoil
(0.20  1.54 mm2 and 1.97  22.2%) than fibronecrotic plaques (1.03  2.12 mm2 and 12.4  28.0%, p 
0.001 and p  0.001, respectively) or fibrocellular plaque (0.74  1.48 mm2 and 8.90  19.8%, p  0.001
and p  0.001, respectively).
Conclusions The BVS shrank in size during the follow-up period. The lesion morphology of stented segments might affect the
degree of late recoil of the BVS. (ABSORB Everolimus Eluting Coronary Stent System First in Man Clinical Investi-
gation; NCT00300131) (J Am Coll Cardiol 2008;52:1616–20) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.024n
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compared with metallic stents, bioabsorbable polymer
tents could have a lower radial strength, resulting in more
tent recoil after implantation, because polymers are more
exible than metals. The bioabsorbable everolimus-eluting
oronary stent (BVS) (Abbott Vascular, Santa Clara, Cali-
ornia) is composed of a high-molecular-weight poly-L-
actic acid (PLLA) backbone, coated with a matrix of
ioabsorbable polymer and everolimus. All components of
he BVS, except for 2 radio-opaque platinum markers on
oth ends of its surface, are expected to be fully metabolized
nd absorbed in the human body between 2 and 3 years
1,2). Although acute recoil of the BVS as assessed by
uantitative coronary angiography (QCA) was slightly but
rom the *Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; and
he †Computer Vision Center, Autonomous University of Barcelona, Bellaterra,
pain.h
Manuscript received June 1, 2007; revised manuscript received August 8, 2008,
ccepted August 18, 2008.ot significantly higher than that of the everolimus-eluting
etallic stent (2), little is known about late mechanical
ehavior of the BVS. In the present study, we evaluated late
ecoil of the BVS and assessed its relationship with lesion
orphology of the stented segments.
ethods
tudy population. Of the 30 patients included in the
BSORB (ABSORB Everolimus Eluting Coronary Stent
ystem First in Man Clinical Investigation) trial, 16 were
nrolled at the Thoraxcenter, Erasmus Medical Center,
otterdam, the Netherlands. The trial has been described in
etail previously (1,2). It was approved by the local ethics
ommittee, and all patients gave written informed consent.
n brief, patients were eligible for the study if they had
ingle de novo native coronary artery lesions that could be
overed with a single BVS. Patients were ineligible if they
ad evolving myocardial infarction, left main coronary
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ccluded lesion, a lesion with moderate-to-heavy calcifica-
ion, angiographically visible thrombus within the target lesion,
r a left ventricular ejection fraction 30%.
tudy procedure. Target lesions were electively treated
ith standard interventional techniques with mandatory
re-dilation and stent deployment at a pressure not exceed-
ng the rated burst pressure (16 atm). Post-dilation with a
alloon shorter than the implanted stent was allowed at
perator discretion. Bailout stenting for edge dissection was
ermitted with metallic stents. At the end of the procedure,
ntravascular ultrasound (IVUS) procedures were performed
ith a 40-MHz IVUS catheter (Atlantis SR Pro, Boston
cientific Corporation, Natick, Massachusetts) with an
utomated pullback system at 0.5 mm/s. After IVUS
xaminations, no other stent-related procedures were added.
ll patients were planned to undergo both a coronary
ngiography and an IVUS examination 6 months after the
nitial procedure.
CA and quantitative IVUS analysis. The QCA was
erformed with the CAAS II analysis system (Pie Medical
V, Maastricht, the Netherlands) by an independent ob-
erver blinded to the clinical and IVUS findings. The
ollowing QCA parameters were computed: minimal lumen
iameter, reference vessel diameter, percent diameter steno-
is, and lesion length. The accuracy of this method has been
eported in detail previously (3).
To analyze and compare the IVUS data consistently, all
VUS examinations were retrospectively electrocardiogram
ECG)-gated with the validated Intelligate method, which
utomatically selects near end-diastolic frames from pre-
ecorded non–ECG-gated IVUS data (4). The IVUS im-
ges of both post-procedure and follow-up studies were
nalyzed by side-by-side viewing, comparing for matched
egments. Only the stented segments were analyzed and
ere identified by the first and the last cross section
ontaining visible stent struts. The lumen, stent, and exter-
al elastic membrane contours were detected with the
alidated software (CURAD QCU Analysis Software,
urad B.V., Wijk bij Duurstede, the Netherlands), which
llows semi-automated detection of the lumen–intima in-
erface and the external elastic membrane in longitudinal
econstructed views of coronary vessels (5,6).
ate stent recoil assessment. Stent recoil was computed
rom measurements of IVUS cross-sectional areas (CSAs),
btained every 0.5 mm. Late absolute stent recoil was
efined as stent area at post-procedure (X)  stent area
t follow-up (Y). Late percent stent recoil was defined as
X  Y)/X  100.
mage-based plaque characterization. The IVUS appear-
nce of the BVS struts is unique and differs from that of
etallic stents. The polymer struts are visible as 2 parallel
ines of echoes without acoustic shadowing (AS), due to the
act that the ultrasound is mainly backscattered at the
nterfaces (blood/polymer interface and polymer/tissue in-
erface) of the struts with the surrounding environment. lherefore, plaque characteriza-
ion of BVS implanted segments
an be assessed without the im-
ge artifacts as seen in IVUS of
etallic stents.
To investigate the possible re-
ationship between the degree of
ate stent recoil and plaque mor-
hology in stented segments,
laque characterization of BVS
mplanted segments was qualita-
ively assessed by IVUS appear-
nce. All acquired CSAs were
lassified into 3 different plaque
ypes: calcific, fibronecrotic, or
brocellular plaque. Each plaque
ype was defined as follows (7–11): calcific plaque: highly
chogenic areas having a density greater than that of the
dventitia and causing AS, possibly combined with rever-
erations; fibronecrotic plaque: plaque components causing
cholucent areas within the plaque combined with AS or
laque having AS without reverberations; and fibrocellular
laque: plaque components other than calcific and fibrone-
rotic plaques. In case several plaque types were identified in
CSA, the predominant plaque type was selected.
tatistical analysis. Statistical analysis was performed with
AS software (SAS Institute Inc., Cary, North Carolina).
ategorical variables were expressed as counts and percent-
ges. Continuous variables were presented as mean values
ith SDs. The Student t test was performed for testing
ifferences of late BVS recoil among 3 different plaque types
f stented segments. To adjust for multiple observations/
atient, with possible correlations of adjacent cross sections,
he t statistic was divided by C  (1  [m  1]), where m
s the number of observations/patient and  is the intraclus-
er correlations (12). The intracluster correlation  is de-
ned as: variance (between patients)/(variance [between
atients]  variance [within patients]). A value of p  0.05
as considered statistically significant.
esults
ll patients were successfully treated and underwent
ollow-up coronary angiography and IVUS procedures at
.0  1.2 months. Only 1 patient received bailout stenting.
total of 484 paired (post-procedure and follow-up) CSAs
ere acquired. Baseline and follow-up results are shown in
able 1. According to the protocol, lesion complexity was
elatively simple: no type C lesion, short lesion length (9.83
.02 mm), large reference vessel diameter (2.96  0.48 mm),
nd mild degree of diameter stenosis (62  13%). Late
bsolute stent recoil was 0.65  1.71 mm2 (95% confidence
nterval [CI]: 0.49 to 0.80 mm2), and late percent stent
ecoil was 7.60  23.3% (95% CI: 5.52% to 9.68%). All
cquired CSAs were qualitatively assessable in terms of
Abbreviations
and Acronyms
AS  acoustic shadowing
BVS  bioabsorbable
everolimus-eluting coronary
stent
CI  confidence interval
CSA  cross-sectional area
ECG  electrocardiogram
IVUS  intravascular
ultrasound
PLLA  poly-L-lactic acid
QCA  quantitative
coronary angiographyesion morphology of stented segments. The fibrocellular,
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54 CSAs, respectively. The relationship between late stent
ecoil and lesion morphology is shown in Figure 1. Late
bsolute and percent stent recoil were significantly less in
alcified lesions (0.20  1.54 mm2 and 1.97  22.2%,
espectively) than in fibrofatty lesions (0.74  1.48 mm2
linical, Lesion, and Procedural Characteristics
Table 1 Clinical, Lesion, and Procedural Characteristics
Patient demographic data (n  16 patients)
Age, yrs 60.9 8.6
Male 11 (69%)
Hypertension 10 (63%)
Hypercholesterolemia 12 (75%)
Diabetes 1 (6%)
Current smoking 4 (25%)
Prior myocardial infarction 2 (13%)
Lesion characteristics (n  16 lesions)
Treated vessel
Right coronary artery 4 (25%)
Left anterior descending 5 (31%)
Left circumflex artery 7 (44%)
ACC/AHA lesion type
Type A 0 (0%)
Type B1 8 (50%)
Type B2 8 (50%)
Type C 0 (0%)
Procedural characteristics
Pre-dilation before stenting 16 (100%)
Post-dilation 12 (75%)
Maximal pressure during entire procedure, atm 16.1 0.89
Stent/artery ratio 0.98 0.16
Clinical success 16 (100%)
QCA results
Pre-procedure
Lesion length, mm 9.83 4.02
Reference vessel diameter, mm 2.96 0.48
Minimal lumen diameter, mm 1.09 0.31
Diameter stenosis, % 62 13
Post-procedure
Minimal lumen diameter, mm 2.45 0.33
Diameter stenosis, % 19 8
Acute gain, mm 1.36 0.46
Follow-up
Minimal lumen diameter, mm 2.00 0.27
Diameter stenosis, % 29 14
Late loss, mm 0.45 0.39
IVUS results (n  484 CSAs)
Post-procedure
Stent area, mm2 6.94 1.47
Follow-up
Stent area, mm2 6.29 1.70
Lumen area, mm2 5.83 1.51
Neointimal area, mm2 0.47 0.58
Late absolute stent recoil, mm2 0.65 1.71
Late percent stent recoil, % 7.60 23.3
alues are mean  SD or n (%).
ACC/AHA American College of Cardiology/American Heart Association; CSA cross-sectional
rea; IVUS  intravascular ultrasound; QCA  quantitative coronary angiography.nd 8.90  19.8%, p  0.001 and p  0.001, respectively) mr in fibronecrotic lesions (1.03  2.12 mm2 and 12.4 
8.0%, p  0.001 and p  0.001, respectively). Although
here was a trend toward more recoil in fibronecrotic lesions
han in fibrocellular lesions, no significant differences in late
bsolute and percent stent recoil were observed between
hese 2 lesion types (p  0.18 and p  0.1, respectively).
iscussion
he present study indicated that the BVS shrank in size
uring the follow-up period. This observation was at vari-
nce with the observed 6 months’ late recoil of the Igaki-
amai stent, which was the first polymeric stent examined
n diseased human coronary arteries (13). Although the
gaki-Tamai stent was composed of the same material
PLLA) as the BVS, it became larger in size (0.71 mm2 at
months according to IVUS analysis). This discrepancy
ould have been caused by the differences in study protocols
nd/or baseline characteristics of the target lesions between
studies. However, the main reason might be associated
ith differences in stent design. Because the Igaki-Tamai
tent was self-expandable, whereas the BVS was balloon-
xpandable, the Igaki-Tamai stent tends to expand gradu-
lly in time until it reaches fully unconstrained dimensions.
The current results also differed from reported late recoil
f metallic stents as assessed by IVUS. The Palmaz-Schatz
tent exhibited only a little recoil (0.1 mm2 and 0.6%) at 4
onths (14). Late recoil of the XIENCE V everolimus-
luting stent (Abbott Vascular), which is a metallic stent
oated with the same antiproliferative drug as in the BVS,
as computed as 0.02 mm2 and 0.3% at 6 months (1,15).
hese changes are in the range of reproducibility measure-
ents. However, it is obvious that the vessel scaffolding
roperties of the BVS have not been maintained for a long
eriod compared with metallic stents, even if the BVS shows a
ood radial strength, similar to metallic stents, immediately
fter deployment (2). This might be due to differences in
aterial components between both stent types. Because poly-
ers are more flexible than metals, there is a potential that
olymer stents are affected by the elastic properties of the
rterial wall more directly and have been compressed steadily.
n addition, because the BVS is designed to be gradually
etabolized, the polymer backbone will lose its structural
ntegrity over time, which could diminish its radial strength
nd lead the stent to shrink. However, no clear image of such
degradation process of the BVS was documented, even when
sing a 40-MHz IVUS catheter, probably due to an insuffi-
ient resolution of IVUS to clarify this phenomenon.
Because the extent of stent recoil is the result of the
alance between the elastic recoil and radial strength of the
tent, along with the elastic properties of the arterial wall, it
an be affected by the plaque characteristics of the stented
egments. The elastic property of the arterial wall is deter-
ined by atherosclerotic plaque constituents. Previous stud-
es revealed the following: 1) calcific plaques had stiffer
echanical properties than other types of plaques and thus
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laques had more elasticity than calcific plaques, but no
ignificant difference was observed between these 2 plaque
ypes (10,11). In concurrence with these statements, the
resent study demonstrated that calcified plaques resulted in
ignificantly less late recoil than the other plaque types and
hat fibrocellular or fibronecrotic plaques induced more late
ecoil than calcified plaques, although no significant differ-
nces in late recoil were observed between these 2 plaque
ypes (Fig. 1). These findings suggest that an IVUS exam-
nation of the target lesion before stenting could be useful to
redict the extent of stent recoil in case of BVS implantation.
tudy limitations. Limitations are the small number of
nrolled patients and that the clinical implication of the
VS shrinkage remains unclear. Target lesions were rela-
ively simple, and late recoil of the BVS might increase in
ore complex lesions. Further investigations are warranted
o determine the recoil properties of the BVS at the time of
ts complete degradation.
onclusions
certain degree of late stent recoil was observed 6 months
Figure 1 Correlation Between Late Recoil of the BVS and the L
Representative intravascular ultrasound images of fibrocellular, fibronecrotic, or ca
plaque are shown at the bottom of the figure. BVS  bioabsorbable everolimus-elfter BVS implantation, indicating that the BVS shrank in sizeuring the follow-up period. The lesion morphology of stented
egments might affect the extent of late recoil of the BVS.
eprint requests and correspondence: Dr. Nico Bruining, Eras-
us Medical Center, P.O. Box 1738, 3000 DR, Rotterdam, the
etherlands. E-mail: n.Bruining@erasmusmc.nl.
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